

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Boill Healthcare Holdings Limited**

### **保集健康控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1246)**

#### **INSIDE INFORMATION**

**(1) DECISION OF THE LISTING COMMITTEE ON  
CANCELLATION OF LISTING;  
(2) RIGHT OF REVIEW AND REVIEW REQUEST OF  
THE DECISION;  
AND  
(3) CONTINUED SUSPENSION OF TRADING**

This announcement is made by Boill Healthcare Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to (i) the announcement of the Company dated 25 July 2024 in relation to suspension of trading of the shares of the Company (the “**Shares**”); (ii) the announcements of the Stock Exchange dated 9 August 2024, 3 December 2024 and 13 February 2025 regarding the Company, which set out, among others, the resumption guidance for the resumption of trading in the Company’s securities (the “**Resumption Guidance**”); (iii) the announcements of the Company dated 16 January 2026 and 25 January 2026 in relation to, among others, the progress in fulfilling the Resumption Guidance and continued suspension of trading; (iv) the announcement of the Company dated 25 January 2026 for the preliminary interim results of the Company for the six months ended 30 September 2024; (v) the announcement of the Company dated 25 January 2026 for the preliminary annual results of the Company for the year ended 31 March 2025; (vi) the announcement of the Company dated 25 January 2026 for the preliminary interim results of the Company for the six months ended 30 September 2025; and (vii) the announcement of the Company dated 25 January 2026 in relation to, among others, the key findings of the independent forensic investigation and the internal control review (collectively, the “**Announcements**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

## **DECISION OF THE LISTING COMMITTEE ON CANCELLATION OF LISTING**

The board of directors of the Company regrets to announce that, on 13 February 2026, the Company received a letter (the “**Letter**”) from the Stock Exchange stating that the Listing Committee of the Stock Exchange (the “**Listing Committee**”) has decided to cancel the listing of the Shares under Rule 6.01A(1) of the Listing Rules (the “**Decision**”), as the Listing Committee considered that the Company had not fulfilled all of the Resumption Guidance and did not resume trading of the Shares on the Stock Exchange by 24 January 2026. In particular, among the Resumption Guidance, the Stock Exchange was of the view that the Company had failed to demonstrate compliance with Rule 13.24 (the Resumption Guidance 3), demonstration of management integrity (the Resumption Guidance 5), internal control review (the Resumption Guidance 6) and disclosure of all material information (the Resumption Guidance 8).

### **RIGHT OF REVIEW AND REVIEW REQUEST OF THE DECISION**

Under Chapter 2B of the Listing Rules, the Company has the right to have the Decision referred to the Listing Review Committee of the Stock Exchange (the “**Listing Review Committee**”) for review within seven business days of the date of issue of the Decision (i.e. 27 February 2026) (the “**Review**”). If the Company decides not to apply for the Review, it is indicated in the Decision that the last day of listing of the Shares will be on 4 March 2026 and the listing of its Shares will be cancelled with effect from 9:00 a.m. on 5 March 2026.

The Company, after reviewing the Decision and discussing with its professional advisers, has lodged a request for the Decision to be referred to the Listing Review Committee for Review on 27 February 2026.

The Directors would like to remind the Shareholders and potential investors that the outcome of the Review is uncertain. Further announcement(s) will be made by the Company in respect of the Review as and when appropriate and in accordance with the requirements of the Listing Rules. Shareholders and potential investors who have any queries about the implications of the delisting of the Shares are advised to seek appropriate professional advice.

### **CONTINUED SUSPENSION OF TRADING**

Trading in the Shares on the Stock Exchange was suspended at the request of the Company with effect from 9:31 a.m. on 25 July 2024. The trading in the Shares will remain suspended until the Stock Exchange is satisfied that the Company fulfills all the Resumption Guidance.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.**

By order of the Board  
**Boill Healthcare Holdings Limited**  
**He Yu**  
*Executive Director*

Hong Kong, 27 February 2026

*As at the date of this announcement, the Company has (i) two executive Directors, namely Mr. Yu Jinlong and Mr. He Yu; (ii) one non-executive Director, namely Dr. Tang Sing Hing, Kenny and (iii) three independent non-executive Directors, namely Ms. Mak Suet Man, Mr. Chan Chi Hang and Mr. Liang Yanan.*